Showing results (1811-1820 of 1,853) with videos related to
Sort By:
Pageof 186
Journal of Managed Care & Specialty Pharmacy|April 29, 2025
Pediatric-onset rare disease therapy pipeline yields hope for some and gaps for many: 10-year projection of approvals, treated patients, and list price revenuesColin M Young, Sharon E Phares, Annie Kennedy, et al.Journal of Managed Care & Specialty Pharmacy|March 28, 2025
Out-of-pocket costs for direct oral anticoagulants and prescription abandonment among patients with nonvalvular atrial fibrillation or venous thromboembolismMaryia Zhdanava, Veronica Ashton, Jill Korsiak, et al.Journal of Managed Care & Specialty Pharmacy|March 28, 2025
Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspectiveJason Shafrin, Shanshan Wang, Jaehong Kim, et al.Journal of Managed Care & Specialty Pharmacy|March 28, 2025
Limited utility of price transparency data for drugsYuvraj Pathak, Elvira Makk Frid, Nico Gabriel, et al.Journal of Managed Care & Specialty Pharmacy|March 28, 2025
Frequency of first generic drugs approved through "skinny labeling," 2021 to 2023Therese J Ziaks, Chukwubuikem M Akanegbu, Alexander C Egilman, et al.Journal of Managed Care & Specialty Pharmacy|April 3, 2025
Assessing variation in US payer coverage of anti-vascular endothelial growth factor therapies for the treatment of age-related macular degeneration, diabetic retinopathy, and diabetic macular edemaJames D Chambers, Molly T Beinfeld, Terry Richardson, et al.Journal of Managed Care & Specialty Pharmacy|February 28, 2025
Treatment patterns, health care resource utilization, and costs of chimeric antigen receptor T-cell vs standard therapy for relapsed/refractory mantle cell lymphoma in the United StatesKarl M Kilgore, Philip K Chan, Christie Teigland, et al.Journal of Managed Care & Specialty Pharmacy|June 2, 2024
Projecting long-term clinical outcomes with larotrectinib compared with immune checkpoint inhibitors in metastatic nonsmall cell lung cancer and differentiated thyroid cancerKangho Suh, Ashley Kang, Gilbert Ko, et al.Journal of Managed Care & Specialty Pharmacy|June 2, 2024
US commercial health plan coverage dynamics in pulmonary arterial hypertension therapiesJulia A Rucker, Molly T Beinfeld, Daniel E Enright, et al.Journal of Managed Care & Specialty Pharmacy|June 2, 2024
Sustaining competition for biosimilars on the pharmacy benefit: Use it or lose itStanton R MehrPageof 186